dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Dent, Rebecca |
dc.contributor.author | O’Shaughnessy, Joyce |
dc.contributor.author | Kim, Sung‑Bae |
dc.contributor.author | Isakoff, S. J. |
dc.contributor.author | Barrios, Carlos |
dc.contributor.author | Antunes de Melo Oliveira, Ana Mafalda |
dc.contributor.author | Turner, Nicholas |
dc.date.accessioned | 2022-06-13T09:09:30Z |
dc.date.available | 2022-06-13T09:09:30Z |
dc.date.issued | 2022-02 |
dc.identifier.citation | Turner N, Dent RA, O'Shaughnessy J, Kim SB, Isakoff SJ, Barrios C, et al. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat. 2022 Feb;191:565–576. |
dc.identifier.issn | 1573-7217 |
dc.identifier.uri | https://hdl.handle.net/11351/7661 |
dc.description | HER2 negatiu; Ipatasertib; PI3K/AKT |
dc.description.sponsorship | This work was supported by Genentech/Roche. Medical writing assistance was provided by Jennifer Kelly, MA (Medi-Kelsey Ltd), funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Breast Cancer Research and Treatment;191 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Medicaments antineoplàstics - Efectes secundaris |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | /adverse effects |
dc.title | Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s10549-021-06450-x |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://doi.org/10.1007/s10549-021-06450-x |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Turner N] Breast Unit, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK. Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK. [Dent RA] Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. [O'Shaughnessy J] Department of Medical Oncology, Texas Oncology, Baylor University Medical Center, US Oncology, Dallas, TX, USA. [Kim SB] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. [Isakoff SJ] Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA. [Barrios C] Latin American Cooperative Oncology Group, Oncology Research Service, Hospital São Lucas, PUCRS, Porto Alegre, RS, Brazil. [Oliveira M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34860318 |
dc.identifier.wos | 000725948900001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |